Yidafan (ivonescimab)

P2, N=42, Not yet recruiting, National University Hospital, Singapore

We report a 56-year-old man with stage IVA pulmonary squamous cell carcinoma (SqNSCLC) who progressed on multiple lines of therapy, including chemotherapy plus pembrolizumab, docetaxel, and the PD-1/VEGF bispecific antibody ivonescimab. Crucially, strict multidisciplinary monitoring confirmed no TB reactivation or dissemination, and no grade ≥3 immune-related adverse events occurred. This case provides the first clinical evidence that, in carefully selected patients with controlled MDR-TB, dual checkpoint blockade with QL1706 is a feasible salvage strategy, provided that TB is rigorously managed.

P1/2, N=286, Not yet recruiting, Akeso

P2, N=49, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Initiation date: Dec 2025 --> Jun 2026

P=N/A, N=37, The affiliated hospital of southwest medical university; The affiliated hospital of southwest medical university

P2, N=25, Recruiting, Cancer Hospital of Chinese Academy of Medical Sciences; Cancer Hospital of Chinese Academy of Medical Sciences

This case report describes a patient diagnosed with cervical squamous cell carcinoma accompanied by hepatic metastases who received first-line therapy with platinum-based chemotherapy in combination with cadonilimab and bevacizumab...Subsequent to disease progression, second-line treatment was initiated with ivonescimab combined with single-agent albumin-bound paclitaxel...To our knowledge, this is the first reported case demonstrating a significant response to ivonescimab in recurrent or metastatic cervical cancer following failure of first-line immunotherapy combined with anti-angiogenic therapy. This case preliminarily validates its anti-tumor activity and safety characteristics, and presents a novel therapeutic strategy for later-line management.

P2, N=47, Not yet recruiting, Swiss Cancer Institute | Trial completion date: Mar 2029 --> Jul 2029 | Initiation date: Mar 2026 --> Jul 2026 | Trial primary completion date: Mar 2028 --> Jul 2028

P1/2, N=66, Recruiting, Memorial Sloan Kettering Cancer Center

P1/2, N=53, Recruiting, Memorial Sloan Kettering Cancer Center

Novel therapeutic approaches are emerging, including PRMT5 inhibitors in MTAP-deficient tumors, TROP-2-directed antibody-drug conjugates (e.g., sacituzumab govitecan), and chimeric antigen receptor (CAR) T-cell therapies targeting mesothelin. Bispecific agents such as bintrafusp alfa and ivonescimab, which co-target various pathways, offer innovative strategies. Despite these advances, TC remains a challenging malignancy with no standardized treatment algorithm. Collaborative efforts across institutions will be essential to accelerate progress and improve outcomes in this rare disease.

P3, N=536, Recruiting, Akeso | Not yet recruiting --> Recruiting